Financial press releases
MEDESIS PHARMA to participate to the World Congress for Clinical Trials in Alzheimer’s Disease, in Madrid at the end of October 2024 (CTAD, Clinical Trials Alzheimer’s Disease)
2023 full-year business and earnings
Termination of the agreement between NICE and GREEN S.A. and Medesis Pharma
Phase 2 clinical trial for the treatment of Alzheimer’s disease
Completion of the 1st phase of double-blind treatment, with good patient retention and acceptance of the treatment – January, 29 2024
2023 first-half business and earnings – October, 27 2023
Participation in the 16th International Clinical Trials on Alzheimer’s Disease (CTAD), in Boston from 24 to 27 October 2023, and presentation of a poster on its current research. – October, 23 2023
End of enrollement of the 68 patients in Medesis Pharma phase 2 clinical study of Nanolithium for the treatment of Alzheimer’s disease – October, 17 2023
Publication of a scientific article in the journal of alzheimer’s disease on the use of lithium for the treatment of alzheimer’s disease – October, 11 2023
MEDESIS PHARMA receives approval from the Montpellier commercial court to open a safeguard procedure – October 3 2023
Medesis pharma recognized as a 2023 prix Galien USA nominee for Best Startup – August 2, 2023
Medesis pharma presents a scientific poster at the international conference of the alzheimer association in Amsterdam – July 13, 2023
Notice of allowance in the United States of the patent protecting the radiation protection treatment against irradiation during a nuclear accident – July 4, 2023
Outcome of the montpellier commercial court ruling in the legal dispute between medesis pharma and bpi france – June 8, 2023
Favorable report from IDSMB experts on the ongoing phase 2 clinical study on Nanolithium in the treatment of Alzheimer’s disease – May 23, 2023
2022 full-year business and earnings – April 17, 2023
Medesis Pharma signs a partnership with Partner International, world leader in transactions between biotechs and pharmaceutical laboratories – April 4, 2023
Medesis pharma sets up bond financing for a potential maximum nominal amount of 2,500,000 euros – March 31, 2023
Medesis Pharma presents a scientific poster at the european RNA leaders congress in Basel – March 13, 2023
New patent filed protecting the technical optimization of the Aonys microemulsion and its efficacy applied for all water-soluble pharmaceutical active ingredients – March 7, 2023
Patent registered in Eurasia to protect the Cesium decorporation drug candidate – Dec. 12, 2022
Medesis Pharma presents a scientific poster at the clinical trials on alzheimer’s disease conference in San Francisco – Nov. 28, 2022
Medesis Pharma announces the constitution of a permanent scientific advisory board of experts in neurodenegerative diseases – Nov. 21, 2022
Medesis Pharma further strengthens its governance – Oct. 4, 2022
Medesis receives a grant from AFM-TELETHON to finance the first phases of the development of NanosiRNA-HD RNA interference therapy for Huntington’s disease – July 20, 2022
Treatment of Alzheimer’s disease with Nanolithium first inclusion of patients in the phase II clinical study – June 13, 2022
Development of NanoManganese for the optimization of radiotherapy in cancer treatment – April 20, 2022
2021 full-year business and earnings – April 13, 2022
Medesis Pharma wishes to accelerate the development of its antinuclear products and provides an update on its strategy – April 5, 2022
U.S. patent protection registration of the future drug allowing the decorporation of cesium – March 24, 2022
Medesis Pharma confirms its eligibility for the PEA-PME – January 14, 2022 (in french only)
Half-year activities and results – September 16, 2021 (in french only)
Repositioning of the NanoManganese program outside the EU after an ANSM refusal – August 26, 2021 (in french only)
Report of the Combined General Meeting – June 15, 2021 (in french only)
Drug candidate development plan for treatment of Huntington disease receives favorable opinion from the EMA – June 3, 2021 (in french only)
Initiation of analyst coverage by Invest Securities – May 7, 2021 (in french only)
Availability of the 2020 Annual Financial Report – April 28, 2021 (in french only)
Annual results and outlook for 2021 (in french only)
Description of the share buyback program and implementation of a liquidity contract – March 12, 2021 (in french only)
Medesis Pharma raises € 7.35m following the very successful IPO on Euronext Paris – February 10, 2021 (in french only)
Medesis Pharma launches its IPO on Euronext Growth Paris – January 26, 2021 (in french only)